NCT04289792 is a Phase 2 clinical trial of nab-Paclitaxel+Gemcitabine in Pancreatic Neoplasms, sponsored by Fujian Medical University Union Hospital.

Who is sponsoring NCT04289792?

NCT04289792 is sponsored by Fujian Medical University Union Hospital.

What drugs are being tested in NCT04289792?

Interventions in NCT04289792: nab-Paclitaxel+Gemcitabine, split-course SBRT.

What condition does NCT04289792 study?

NCT04289792 studies Pancreatic Neoplasms.

Is NCT04289792 still recruiting?

NCT04289792 is currently status unknown. Last updated 16 February 2023.

Last reviewed 2023-02-16 · How we verify

NCT04289792

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer

Status unknown Phase 2 Last updated 16 February 2023

What this trial tests

Phase 2 trial testing nab-Paclitaxel+Gemcitabine in Pancreatic Neoplasms in 27 participants. Status unknown.

Timeline

9 May 2020

Primary endpoint
9 May 2024

9 May 2025

Quick facts

Lead sponsor	Fujian Medical University Union Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	9 May 2020
Primary completion	9 May 2024
Estimated completion	9 May 2025
Sites	1 location across China

Drugs / interventions tested

nab-Paclitaxel+Gemcitabine
split-course SBRT

Conditions studied

Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →

Sponsor

Fujian Medical University Union Hospital

Who can join

Adults 18 to 70, any sex, with Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and locally advanced unresectable pancreatic cancer patients with sequential investigator selection (IC).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines.
Cellini F, Arcelli A, Simoni N, Caravatta L, et al · · 2020 · cited 31× · PMID 32610592 · DOI 10.3390/cancers12071729
Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial.
Zheng R, Wang C, Huang X, Lin Q, et al · · 2020 · cited 2× · PMID 33154057 · DOI 10.1136/bmjopen-2020-039900
Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.
Hegde S. · · 2021 · PMID 33994737 · DOI 10.1007/s13193-020-01192-6

Verify or expand the search:

Other recruiting trials for Pancreatic Neoplasms

Currently open trials in the same condition.

NCT07504471 — Hepatic Arterial Infusion of Sodium Bicarbonate (NaHCO3) Combined With NASOX Regimen and Programmed Death-1 (PD-1) Inhib · Phase 2 · recruiting
NCT07139236 — Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD · recruiting
NCT06885697 — Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Includi · Phase 1 · recruiting
NCT06939023 — Laparoscopic Versus Robot-assisted Left-sided Pancreatectomy for Benign and Pre-malignant Lesions (DIPLOMA-3) · NA · recruiting
NCT06953193 — Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia · NA · recruiting

Other Fujian Medical University Union Hospital trials

Trials by the same sponsor.

NCT07406815 — The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Inva · Phase 3 · not yet recruiting
NCT07444983 — Rezvilutamide for High-Risk Prostate Cancer After Surgery · NA · not yet recruiting
NCT07493070 — Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca · NA · active not recruiting
NCT07389889 — Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nod · NA · not yet recruiting
NCT07303231 — The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esoph · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04289792 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fujian Medical University Union Hospital
Last refreshed: 16 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04289792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing